| T |
|
TAFI 325/Ile Genotype in Old Population of Northern Italy
|
| Mari D, Coppola R, Castaldi D, La Marca S, Moroni B, Suffritti C, Provenzano R |
| |
|
TAFI Gene Polymorphisms and Plasma TAFI Levels: A Trans-Ethnic Association Study
|
| Frere C, Tregouet DA, Morange PE, Saut N, Kouassi D, Tiret L, Juhan-Vague I, Alessi MC |
| |
|
TAFIa Treatment of High Molecular Weight Fibrin Degradation Products Reduces the Ability of Plasminogen to Protect tPA from Inhibition by PAI-1
|
| Cook PM, Schneider MM, Nesheim ME |
| |
|
Targeted Disruption of Mouse Ortholog of the Human MYH9 Responsible for Macrothrombocytopenia with Different Organ Involvement: Hematological, Nephrological, and Otological Studies of Heterozygous KO Mice
|
| Matsushita T, Hayashi H, Kunishima S, Hayashi M, Ikejiri M, Yuzawa Y, Adachi T, Hirashima K, Sone M, Yamamoto K, Takagi A, Katsumi A, Nezu N, Nakashima T, Kojima T, Saito H, Naoe T |
| |
|
Targeting of the Direct FXa Inhibitor TAP via the Fusion of a Single-chain Antibody Directed Against a LIBS Epitope on GPIIb/IIIa Provides Effective Anticoagulation without Bleeding Time Prolongation
|
| Stoll P, Bassler N, Hagemeyer CE, Schmidt R, Ahrens I, Schwarz M, Bode C, Peter K |
| |
|
TECHNOTHROMBIN® TGA a Novel Thrombin Generation Assay Suitable for the New Routine Coagulation Analyzer Ceveron® Alpha
|
| Kaufmann V, Mager J, Unzeitig G, Eschrich R, Voigt MW, Váradi K, Turecek PL, Binder BR |
| |
|
TECHNOZYM® ADAMTS 13 Assays for Analyzing the vWF Cleaving Protease ADAMTS 13
|
| Vetr H, Colle S, Geiter S, Zhegu Z, Scheifflinger F, Rieger M, Breitwieser A, Binder BR |
| |
|
Telephone Consultation Provided by the Hemophilia Treatment Centre – A Significant Part of the Service
|
| Seroski W, Goldsmith R, Decker K, Almonte T, Walker I, Pai M, Chan AKC |
| |
|
Ten Year Experience of TKR in Hemophilic Patients: The Surgical Unsolved Problems
|
| Solimeno LP, Perfetto OS |
| |
|
Terminal Dry-Heat (TDH) Treatment, As Part of the Octanate® Production Process, Contributes to the High Virus Safety Preserving the Structural and Functional Properties of the Concentrate
|
| Kannicht C, Gruber G, Neisser-Svae A, Stadler M |
| |
|
Testing for Anticardiolipin Antibodies and Anti-Beta2-Glycoprotein I. Is It Useful? A Scientist's Perspective
|
| Galli M, Barbui T |
| |
|
Tetramethylpyrazine Inhibits Apoptotic Cell Death of Cultured Endothelial Cells Induced by Tumor Necrosis Factor-alpha
|
| Zhao Y, Xiong SL, Wen ZB, He XF, He SL |
| |
|
TF:FVIIa-Induced CREB Activation Occurs Via a Mechanism That Is Distinct from That Involved in TF:FVIIa-Induced STAT5 Activation
|
| Versteeg HH, Slofstra SH, Spek CA, Richel DJ, Peppelenbosch MP |
| |
|
TFPI Degradation by Neutrophil Proteases: Potential Implications in Acute Myocardial Infarction
|
| Steppich B, Mattisek C, Moog P, Sobezyk D, Ott I |
| |
|
Thalidomide Affects Early Phases of VEGF Stimulated Angiogenesis in Human Endothelial Cells
|
| Pawlowska Z, Komorowski J, Jerczynska H, Siejka A, Baranska P, Lawnicka H, Stepien H |
| |
|
The b1-Tubulin Q43p Functional Polymorphism Reduces the Risk of Cardiovascular Disease by Modulating Platelet Function and Structure
|
| Freson K, Wittevrongel C, Thys C, Defoor J, Van Hees L, De Vos R, Vermylen J, Van Geet C |
| |
|
The b-Fibrinogen -1420G/A Promoter Polymorphism Influences Transcription through Differential Binding of FOXA/HNF3 and May Explain the Association of the -1420A-Containing Haplotype with Elevated Plasma Fibrinogen
|
| Ellis SA, Wragg S, Davidson AO, Green FR |
| |
|
The Marburg I Polymorphism of Factor Seven-Activating Protease Is Not Associated with Venous Thrombosis
|
| van Minkelen R, de Visser MCH, Vos HL, Bertina RM, Rosendaal FR |
| |
|
The -3459 A > GSNP in the CD40L Gene Predicts Plasma Concentrations and Outcome in Patients with Acute Coronary Syndrome (FRISC-II)
|
| Mälarstig A, Lindahl B, Wallentin L, Siegbahn A |
| |
|
The 4g/5g Polymorphism of the Pai-1 Gene is Associated with Cerebrovascular Disease Development in Childhood and Juvenile Period
|
| Sirotkina O, Merkulova A, Chukhlovina M, Elchaninov P |
| |
|
The -675 4G/5G Plasminogen Activator Inhibitor-1 Promoter Polymorphism in House Dust Mite Sensitive Allergic Asthma Patients
|
| Pampuch A, Di Castelnuovo A, Kowal K, de Gaetano G, Bodzenta-Lukaszyk A, Donati MB, Iacoviello L |
| |
|
The 80+ Hemorrhagic Cohort Study – Rates, Severity and Predictors of Major Hemorrhage in a Cohort of Anticoagulated Atrial Fibrillation Patients
|
| Brophy MT, Cantillon CE, Young M, Gagnon D, Fiore LD |
| |
|
The 807C/T Polymorphism in the a-Subunit of Integrin a2b1 Modulates Platelet Adhesion onto Immobilized Collagen Under Arterial Flow Conditions
|
| Loncar R, Stoldt V, Thomas V, Zotz RB, Scharf RE |
| |
|
The A2 Domain of Coagulation Factor VIII Shares Residues Critical for Interaction with Three Members of LDL Receptor Superfamily – LRP, VLDL and Megalin Receptors
|
| Makogonenko E, Sarafanov A, Pechik I, Andersen O, Ananyeva N, Radtke P, Strickland D, Saenko E |
| |
|
The ABO Blood Group Genotype and Factor VIII Levels as Independent Risk Factors for Venous Thromboembolism
|
| Tirado I, Mateo J, Soria JM, Oliver A, Martínez-Sanchez E, Vallvé C, Borrell M, Urrutia T, Fontcuberta J |
| |
|
The Absolute Risk of Venous Thrombosis after Air Travel (WRIGHT Study)
|
| Kuipers S, Schreijer AJM, Cannegieter SC, Middeldorp SBüllerHR, Rosendaal FR |
| |
|
The Accuracy of the Wells Pretest Probability Assessment Model for Proximal Deep Vein Thrombosis When Applied by Emergency Department Doctors in South Australia
|
| Chunilal SD, Lake JD, Davey M, Spike J, Johanson S, Williams A, Kyriacou M, Charles P, Duncan E, Lloyd JV |
| |
|
The Activation of Intracoronary Monocytes and Platelets Correlates with Cardiac Enzyme Levels in Patients Undergoing Coronary Artery Stenting
|
| Connor DE, Ma DDF, Baron DW, Muller DW, Roy P, Wilson S, Joseph JE |
| |
|
The Activation of Mouse Fibroblasts by Antiphospholipid Antibodies Requires TLR2
|
| Satta N, Dunoyer-Geindre S, Fish RJ, Reber G, Boehlen F, Kruithof EKO, de Moerloose P |
| |
|
The Activity of GPG-290, An Antagonist of vWF-mediated Platelet Capture, Can Be Rapidly Monitored Using the PFA-100™ Assay
|
| Huang Q, Sako D, Schaub RG, Shaw GD |
| |
|
The Additional Presence of Lupus Anticoagulants in 300 Patients with Anticardiolipin Antibodies Increases the Risk of Coincidental Venous and Arterial Thrombosis
|
| Miesbach W, Putz G, Asmelash G, Scharrer I |
| |
|
The Affinity of Protein C for the Thrombin-Thrombomodulin Complex Is Determined in a Primary Way by Active Site-Dependent Interactions
|
| Lu G, Chhum S, Krishnaswamy S |
| |
|
The Analysis of Fibrinolytic Factors on the Isolated Hepatocyte from Mice in the Process of Liver Regeneration
|
| Okada K, Ueshima S, Kawao N, Kawada S, Okamoto C, Matsuo O |
| |
|
The Angiotensin-Converting Enzyme Gene Insertion/Deletion Polymorphism and Effects of Quinapril and Atorvastatin on Haemostatic Parameters in Patients With Coronary Artery Disease
|
| Potaczek DP, Undas A, Iwaniec T, Szczeklik A |
| |
|
The Annexin II Heterotetramer is a Receptor for the Plasmin-Induced Signaling in Human Peripheral Monocytes
|
| Syrovets T, Laumonnier Y, Burysek L, Pitterle K, Simmet Th |
| |
|
The Antiplatelet Activity of Hesperetin Is Mainly Mediated By Inhibition of PLCg2 Phosphorylation and Its Downstream Signal Transduction
|
| Jin YR, Cho MR, Lim Y, Lee JJ, Pyo HB, Yun YP |
| |
|
The Antithrombotic Activity of Kininogen is Mediated by Inhibitory Effects of Domain 3 on Thrombin-Induced Platelet Activation, In Vivo
|
| Hassan S, Khan M, Isordia-Salas I, Sainz I, Bradford HN, Kashem S, Liu B, Sartor RB, Colman RW |
| |
|
The Antithrombotic Effect of the Fibrinogen-Binding Fragment of Staphylococcus Aureus Clumping Factor A
|
| Liu CZ, Shih MH, Tsai PC |
| |
|
The Application of New Diagnostic Guidelines in Type 1 von Willebrand Disease to Patients Previously Diagnosed Under the UK 1995 Guidelines. A Single Centre Paediatric Experience
|
| Dutt T, Smith L, Mackett N, Benfield C, Caswell M, Keenan R |
| |
|
The Assembly of the Factor-X Activating Complex on Activated Platelets is Down-regulated by the Formation of Lipid Rafts that Remove the Substrate (Factor X) and the Cofactor (Factor VIIIa) from the Enzyme (Factor IXa)
|
| Ahmad SS, Su Y-C, Walsh PN |
| |
|
The Association Between Diabetes and Venous Thromboembolism in African Americans and Caucasians and the Relationship with Peroxisome Proliferator-Activated Receptor Polymophisms
|
| Hooper W, Austin C, Lally H, Ellingsen C, Dowling D, Nicole F, Carolyn W |
| |
|
The Association Between Tissue Factor-Exposing Microparticles and the Activation of the Coagulation System in Cancer Patients
|
| Hron G, Kollars M, Kornek G, Quehenberger P, Eichinger S, Kyrle PA, Weltermann A |
| |
|
The Association of Arterial Thrombosis and Polymorphisms of Platelet Glycoproteins and von Willebrand Factor in the Chinese Population
|
| Ruan C, Dai KS, Shi JM, Gao WQ, Yu ZQ |
| |
|
The Association of Prothrombin A19911G Polymorphism with Plasma Prothrombin Activity and Venous Thrombosis in a Large Population-Based Case-Control Study; Results of the MEGA Study
|
| Chinthammitr Y, Doggen CJM, Vos HL, Rosendaal FR |
| |
|
The Behavior of Anticardiolipin Antibodies Levels in Patients with Venous Thromboembolism
|
| Martinez AM, Rodrigues CA, Morelli VM, Noguti MAE, Andrade LEC, Lourenço DM |
| |
|
The Beige Mutation Is Atheroprotective in Apolipoprotein E-Deficient Mice
|
| Petrovan RJ, Curtiss LK |
| |
|
The Benefit-to-Risk Ratio of Fondaparinux Thromboprophylaxis in Patients Undergoing Major Orthopedic Surgery Is Independent of Age
|
| Kwong LM, Bauer KA, Eriksson BI, Lassen MR, Turpie AGG |
| |
|
The C1418T Polymorphism in the Thrombomodulin Gene is Associated with Increased Levels of Circulating Activated Protein C and with Reduced Risk of Venous Thromboembolism
|
| Medina P, Navarro S, Estellés A, España F |
| |
|
The Canadian Hemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT): Results of the Reliability and Validation Study
|
| McCusker PJ, Bradley CS, Wakefield CD, Barnard D, Blanchette VS, Young NL |
| |
|
The CDC Hemostasis and Thrombosis Centers (HTC) Pilot Sites: Early Data from the Patient Registry
|
|
| |
|
The Circulating Progenitor in Intimal Hyperplasia: Could It Be the Fibrocyte?
|
| Varcoe R, Medbury H, Vicaretti M, Guiffre A, Fletcher J |
| |
|
The Clinical Probability Score and D-dimers Are Not Recommended in Elderly Patients Suspected for Having Deep Vein Thrombosis
|
| Schutgens R, Haas F, Biesma D |
| |
|
The Clinical Significance of Matrix Metalloproteinases Production by Bone Marrow Mononuclear Cells from Patients with Chronic Myeloid Leukemia
|
| Hu X-H, Bai X, Ding K-Y, Ruan C-G |
| |
|
The Cofactor Effect of the B Domain Of Coagulation Factor V on Factor Va Inactivation by Activated Protein C
|
| Kalafatis M, Beck DO |
| |
|
The Combination of LA with Antibodies to B2-Glycoprotein I (anti-B2GPI) and Prothrombin (anti-PT) Predicts a Higher Risk of Thrombosis
|
| Forastiero R, Martinuzzo M, Pombo G |
| |
|
The Comparison of Thrombophilic Potential of F V Leiden and F II20210A in Heterozygous Form in Individuals from the East Bohemian Region
|
| Dulí[ccaron]ek P, Malý J, Beránek M |
| |
The Concerted Action on Neutralizing Antibodies in Severe Haemophilia A
(Canal Study): Preliminary Findings
|
| Gouw SC |
| |
|
The Contemporary Presence of Elevated Levels of Factor VIII and PAI-1 Is a Risk Factor for Recurrent Thromboembolism. A Retrospective Case–Control Study
|
| Ciuti G, Marcucci R, Blagojevic J, Lapini I, Lenti M, Poli D, Antonucci E, Gensini GF, Abbate R, Prisco D |
| |
|
The Contribution of Cosegregation to the Absolute Risk of Venous Thromboembolism (VTE) in Relatives with Either the Prothrombin G20210A Mutation, High Factor VIII : C Levels or Mild Hyperhomocysteinemia
|
| Van de Poel MHW, Coppens M, Middeldorp S, Hamulyak K, Veeger NJGM, Prins MH, Büller HR, van der Meer J |
| |
|
The Contribution of Somatic Mutations in an Antibody against Factor VIII to the Kinetics of Factor VIII Binding and Inhibition of Factor VIII Activity
|
| Gestel D, Van Stempvoort G, Moret EE, Mertens K |
| |
|
The Correlation among Tissue Factor Pathway, Endothelial Damage Parameters and Lipid Profile in Children with Type 1 Diabetes Mellitus
|
| Balci D, Biner B, Demir M, Karasalihoglu S, Azcan S |
| |
|
The Cost of Care of Hemophilic Patients without Inhibitors: The Coche Study
|
| Gringeri A, Scalone L, Di Stasi F, Mannucci PM, Mantovani LG |
| |
|
The COX-2 G/C-765 Polymorphism Modulates the Occurrence of Cerebrovascular Ischemia
|
| Colaizzo D, Tiscia T, Foti L, Vergura P, Sonni P, Cappucci F, Grandone E, Toni D, Margaglione M |
| |
|
The Crystal Structure of Unliganded Thrombin Identifies Regions Involved in Allosteric Regulation by Thrombomodulin
|
| Zubiaga M, Chacko C, Seitova A, Drown P, Mather T |
| |
|
The CXCL 16 Chemokine Is Induced by Angiotensin II in the U-937 Human Monocytic-Derived Cell Line
|
| Weinstein PM, Phillips DJ, League SC, Hooper WC |
| |
|
The D-dimer (DD) Test to Establish the Duration of Anticoagulation after a First Unprovoked Episode of Venous Thromboembolism (VTE); the Prospective Randomized ‘Prolong’ Study on behalf of the Italian Federation of Anticoagulation Clinics (FCSA)
|
| Palareti G, Tosetto A, Cosmi B, Legnani C, Brusi C, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Iorio A, Tripodi A |
| |
|
The D-Dimer Concentration Increases with Age Causing a Marked Effect on the Assay Specificity: Is the D-Dimer Assay Useful As an Exclusion Test in the Elderly?
|
| Harper PL, Theakston E, Ockelford PA |
| |
|
The Detection of Lupus Anticoagulants in Hemophiliacs: The Need for Different Assay Systems
|
| ME Mancuso, E Santagostino, PL Meroni, M Clerici, V Chantarangkul, R Bader, A Tripodi, PM Mannucci |
| |
|
The Detection of the Platelet Activation by Flow Cytometry in the Patients with Pre-eclampsia
|
| Yi ZS, Zhou SY, Meng FY, Feng R, Liu QF, Lin R, Sun J |
| |
|
The Development of a Protocol for Lepirudin Therapy Monitoring
|
| Malan E, Butler J, Gan TE |
| |
|
The Development of a VTE Risk Management Protocol for Orthopaedic Patients within a large General Hospital
|
| Keenan J, Nokes TJC |
| |
|
The Development of Transplanted Rat Prostate Tumors in vivo Is Impaired by Reduced Tissue Factor Expression
|
| Liang Z, Song H, Wolter W, Pollard M, Suckow Mark, Rosen ED |
| |
|
The Diagnosis and the Estimated Incidence of Heparin-Induced Thrombocytopenia in the Critically Ill According to ISTH SSC Criteria
|
| Wester JPJ, Leyte A, Porcelijn L, Lo K, Bosman RJ, Oudemans-van Straaten HM, van der Spoel JI, Zandstra DF |
| |
|
The Distribution Of Central, Segmental And Sub-Segmental Pulmonary Emboli In Multi- And Single-Row Helical CT
|
| Nijkeuter M, Sohne M, Kruip MJHA, Leebeek FWG, Kwakkel-van Erp JM, Ullmann E, Buller HR, Prins MH, Huisman MV, on behalf of the Christopher-study investigators |
| |
|
The EACH Registry: A Prospective European Registry of Acquired Haemophilia (AH)
|
| Baudo F, Collins P, Huth-Kühne A, Levesque H, Marco P, Nemes L, Tengborn L |
| |
|
The Effect of a Second Generation Inhibitor of p38 MAP Kinase on Platelet Function
|
| Covic L, Mohanlal R, Kuliopulos A |
| |
|
The Effect of ABO Blood Group Genotypes on the Loading of von Willebrand Factor with A and B Antigens
|
| Morelli VM, de Visser MCH, van Tilburg NH, Vos HL, Eikenboom HCJ, Rosendaal FR, Bertina RM |
| |
|
The Effect of Chinese Danggui and PDGF on Thrombopoiesis in Irradiated Mice
|
| Yang M, Li K, Li CK, Pong NH, Sung RYT, Chong BH, Fok TF |
| |
|
The Effect of Continuous-flow Automated Plateletpheresis on Fibrinolytic Activity of Donor's Plasma
|
| Boczkowska-Radziwon B, Radziwon P, Smoktunowicz M, Kloczko J |
| |
|
The Effect of Corn Trypsin Inhibitor on Whole Blood Thrombin and Thrombus Generation Parameters
|
| Tappenden KA, Gallimore MJ, Evans G, Winter M, Jones DW |
| |
|
The Effect of Coronary Distal Embolisation on Myocardial Blood Flow and Platelet Activation
|
| Bang KWA, Charron T, Puley G, Quiang B, Shakoor S, Strauss BH, Freedman J |
| |
|
The Effect of Factor Va on Prothrombin-Membrane Binding
|
| Krisinger MJ, Pryzdial ELG, MacGillivray RTA |
| |
|
The Effect of Factor VIIa Gla Domain Removal on in vitro Factor X Activation
|
| Persson E, Ostergaard H |
| |
|
The Effect of Fibrin Degradation Products on Neuroendocrine Cells
|
| Petrova Y, Kalashnik O, Chorna N, Platonova T, Cederholm-Williams S, Skok M |
| |
|
The Effect of Platelet Count on the Thrombelastograph® (TEG) Parameters
|
| Roeloffzen WWH, Bosman L, Kluin-Nelemans JC, de Wolf JThM |
| |
|
The Effect of Platelets on Fibrin Gel Structure Formed in the Presence of Recombinant Factor VIIa in Haemophilia Plasma and in Plasma From a Patient with Glanzmann Thrombasthenia
|
| He S, Jacobsson EG, Hedner U |
| |
|
The Effect of rFVIIa on Thrombin Generation, Whole Blood Clot Formation, and Resistance to Fibrinolysis under Conditions Mimicking Hemophilia A
|
| Svendsen MS, Kristensen AT, Tornehave D, Rojkjaer R |
| |
|
The Effect of SC Injection of Heparins of Different Molecular Weight on Thrombin Generation – Consequences for the Question of Monitoring Heparin Treatment
|
| Al Dieri R, Alban S, Béguin S, Hemker HC |
| |
|
The Effect of Statin Therapy on Coagulation and Fibrinolysis in Patients with Heterozygous Familial Hypercholesterolemia
|
| van Heerde WL, Lap P, Loof A, van Tits LJ, Stalenhoef AFH |
| |
|
The Effect of TFPI On Thrombin Generation: a Mathematical Model
|
| Vystavkin AI, Khanin MA |
| |
|
The Effect of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) on Tissue-Type Plasminogen Activator (t-PA) and Urokinase-Type Plasminogen Activator (u-PA) Induced Fibrinolysis in a Plasma Clot Lysis Assay
|
| Harris SL, Gallimore MJ, Jones DW, Winter M |
| |
|
The Effect of Thrombin Concentration on Fibrin Clot Structure Imaged by Multiphoton Microscopy and Quantified by Fractal Analysis
|
| Bateman RM, Leong H, Walley KR, Podor TJ |
| |
|
The Effect of Two Strenuous Physical Exercise Bouts on the Activation of Blood Cells
|
| Degerstrom J, Osterud B |
| |
|
The Effects of Clopidogrel and Nadroparine on Elevated Thrombolytic Risk and Apoptotic Process in Hypercholesterolemia
|
| Ozsavci D, Sener A, Oba O, Demirel GY, Uras F, Hekim N, Yardimci KT |
| |
|
The Effects of Isometric and Treadmill Exercise on Platelet and Endothelial Function in Patients with Intermittent Claudication
|
| Collins P, Ford I, Ball D, Macaulay E, Greaves M, Brittenden J |
| |
|
The Effects of Platelets on Activation Threshold of the Coagulation System
|
| Khanin MA, Druzhinin AV |
| |
|
The Effects of Supra-Normal Protein C Levels on Markers of Coagulation, Fibrinolysis and Inflammation in a Human Model of Endotoxemia
|
| Spiel A, Firbas C, Mayr F, Schmidt B, Knöbl P, Varadi K, Jilma B |
| |
|
The Effects of Surgery on Platelet and Endothelial Function in Patients with Peripheral Arterial Disease and Severe Limb Ischaemia
|
| Ford I, Collins P, Ball D, Macaulay E, Greaves M, Brittenden J |
| |
|
The Efficacy and Safety of Thromboprophylaxis after Acute Ischemic Stroke: What Agent and Which Dose?
|
| Kamphuisen PW, Agnelli G |
| |
|
The Eskimo Diet: More Than Omega-3 Fatty Acids
|
| Osterud B, Elvevoll EO, Breimo E, Brox J, Eilertsen KE, Lund T, Olsen JO |
| |
|
The Evaluation of Disfunction of Endothelium in Patients with Atherosclerosis of Carotid System and Reversible Neurological Deficit
|
| Ionova V, Suslina Z, Maximova M, Tanashian M |
| |
|
The Expression of Recombinant Adeno-Associated Virus/Human Coagulant Factor IX Gene in Human/Rat Gut Epithelial Cells
|
| Ma YY, Chen FP, Du JW, Chen Y, Peng JQ, Wu XB, Jie QZ |
| |
|
The Expression of von Willebrand Factor Antigen Differ Between Deep Vein Thrombosis and Pulmonary Embolism
|
| Söderberg M, Brohult J, JorfeldtLärfars LG |
| |
|
The Factor V Leiden and Prothrombin 20210G>A Mutations as Risk Factors for Miscarriage during the First Pregnancy: The Matched Case–Control ‘Big NOHA First’ Study
|
| Gris JC, Lissalde-Lavigne G, Cochery-Nouvellon E, Mercier E, Perneger T, Daurès JP, Quéré I, Dauzat M, Marès P |
| |
|
The Factor VII Activating Protease (FSAP) Is an Inhibitor of Neointimal Lesion Formation. Comparison with the Marburg I SNP (G511E) of FSAP
|
| Sedding D, Daniel J-M, Muhl L, Brunsch H, Hersemeyer K, Braun-Dullaeus R, Tillmanns H, Kemkes-Matthes B, Preissner KT, Kanse SM |
| |
|
The Factor VIII/von Willebrand Factor Antigen (FVIII/VWF : Ag) Ratio in Determining VWF Defects in Patients with von Willebrand Disease Type 1: Results from the European Multicenter MCMDM-1VWD Study
|
| Federici AB, Goudemand J, Bader R, Caron C, Tosetto A, Eikenboom JCJ, Peake I, Goodeve A, Rodeghiero F, Castaman G, Batlle J, Meyer D, Mazurier C, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F |
| |
|
The Factor XI Deficiency Database: An Interactive Web Database of Mutations, Phenotypes and Structural Analysis Tools
|
| O’Connell NM, Saunders RE, Lee CA, Perry DJ, Perkins SJ |
| |
|
The Fibrinogen Aa R16C Mutation Results in Fibrinolytic Resistance
|
| Flood VH, Al-Mondhiry HA, Farrell DH |
| |
|
The First Homozygous Family for Factor II G20210A Mutation in Latin America
|
| Cadavid AP, Cardona H, Cardona-Maya W, Román A, Alvarez L, Castaneda SA, Martínez J, Torres JD, Tobón LI, Bedoya G |
| |
|
The Functional Significance of the Autolysis Loop of Protein C and Activated Protein C
|
| Rezaie A, Yang L, Manithody C |
| |
|
The G1691A Factor V and G20210A Prothrombin Gene Mutations Are Not Associated to an Increased Risk of Venous Thromboembolism (VTE) in Patients with Gastrointestinal (GI) Carcinoma
|
| Mandalà M, Falanga A, Cremonesi M, Zaccanelli M, Floriani I, Rosti A, Viganò MG, Cazzaniga M, Cabiddu M, Barni S |
| |
|
The G20210A Prothrombin Gene Mutation and the Plasminogen Activator Inhibitor (PAI) 5G/5G Genotype Increase the Risk of Premature Onset of Severe Preeclampsia
|
| Gerhardt A, Goecke TW, Beckmann MW, Wagner K, Tutschek B, Bender HG, Scharf RE, Zotz RB |
| |
|
The G20210A Prothrombin Variant (PT-G20210A) and the Risk of Thromboembolism and Foetal Loss in Pregnant Women: A Retrospective Cohort Study
|
| Tormene D, Zerbinati P, Perlati M, Rigo F, Vanzan A, Rossetto V, Fadin M, Tognin G, Pagnan A, Simioni P |
| |
|
The Generation of Thrombin by High Dose Recombinant Factor VIIa Can Be Mimicked by Lower Factor VIIa Concentrations Combined with Tissue Factor
|
| Lau H, Zhang Y, Chan2 R, Teitel JM |
| |
|
The Haplotype Structure of the von Willebrand Factor (VWF) Gene Promoter Indicates Balancing Selection
|
| Johansson AM, Säll T, Lethagen S, Sterner M, Halldén C |
| |
|
The Hemostatic State in Cancer Patients: The Relationship Between Hypercoagulable Markers and Cancer Prognostic Markers
|
| Mousa SA, Alizadeh H, Al-Tajer S |
| |
|
The Heparins and Cancer: Review of Clinical Trials and Biological Properties
|
| Castelli R, Porro F, Tarsia P |
| |
|
The Ig-ITIM Superfamily Member, PECAM-1 Regulates the ‘Outside-in’ Signalling Properties of Integrin aIIbb3 in Platelets
|
| Wee JL, Jackson DE |
| |
|
The Impact of Acquired Thrombophilia on Maternal and Fetal Wellbeing in a Low-risk Population
|
| Cooley SM, Donnelly JC, Walsh T, Sarkar R, Geary MP, Gillen J, Banks J, Malley AO, Mahon CM |
| |
|
The Impact of Factor XIII Polymorphisms, FXIIIa T204P, P506L and Factor XIIIb Polymorphism H95A, on Myocardial Infarction
|
| Cui J, Randell E, Renouf J, Sun G, Han F-Y, Green R, Xie Y-G |
| |
|
The Impact of Symptom Duration on Plasma Fibrin D-Dimer Analysis in Deep Vein Thrombosis
|
| Giordano KF, Wysokinski WE, Pruthi R, Grill DE, McBane II RD |
| |
|
The Impact of Tissue Factor Single Nucleotide Polymorphisms on Risk, Outcome and Plasma levels in Acute Coronary Syndrome
|
| Mälarstig A, Tenno T, Johnston N, Lagerqvist B, Axelsson T, Syvänen A-C, Wallentin L, Siegbahn A |
| |
|
The Importance of PDE3A in the Regulation of Platelet Aggregation
|
| Sun B, Hockman S, Manganiello V, Kambayashi J |
| |
|
The Importance of the Low-Density Lipoprotein Receptor-Related Protein (LRP) and Megalin Receptor in the Clearance of Factor VIII in Humans
|
| Boekhorst J, de Vries M, van Hoogen PCM, van Kraaij MGJ, Nováková IRO, Verbruggen HW, van Heerde WL |
| |
|
The Incidence and Outcome of Intracranial Hemorrhage in Newborns with Hemophilia: Analysis of the Nationwide Inpatient Sample (NIS) Database
|
| Tarantino MD, Brusky RM |
| |
|
The Incidence and Penetrance of Common VWF Gene Mutations in a Cohort of Type 1 VWD Patients: Results from the EU Funded MCMDM-1VWD Project
|
| Hashemi M, Peake I, Goodeve A, Rodeghiero F, Castaman G, Federici A, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen LS, Pasi J, Hill F |
| |
|
The Incidence of Heparin-Induced Thrombocytopenia in Medical Patients Treated with Low-Molecular-Weight Heparin: A Prospective Cohort Study
|
| Prandoni P |
| |
|
The Incidence of Venographically Detected Deep Vein Thrombosis after Knee Arthroscopy without Thromboprophylaxis
|
| Hoppener MR, Ettema HB, VeegerBüller NHR, van der Meer J |
| |
|
The Influence of Bivalirudin on Tissue Factor-Initiated Thrombin Generation
|
| Butenas S, Orfeo T, Brummel-Ziedins KE, Mann KG |
| |
|
The Influence of Previous or Currently Active Cancer on Venous Thromboembolism Prophylaxis Prescribing Practices in Acutely Ill Medical Patients
|
| Chong BH, Kakkar AK, Tapson VF, Decousus H, Monreal M, Nakamura M, Pini M, Piovella F, FitzGerald G, Anderson FA, Jr.9 |
| |
|
The In-Hospital Cost of Thrombosis: A Preliminary Economic Analysis
|
| Rota LL, Grizzi F |
| |
|
The Interaction of Factor VII Activating Protease (FSAP) with Growth Factors Influences Vascular Cell Proliferation and Migration
|
| Muhl L, Preissner KT, Kanse SM |
| |
|
The Interaction of Platelets-tumor Cell Complexes with Vitronectin
|
| Wu YP, de Boer HC, Bloemendal HJ, Voest EE, Groot de PhG, Gebbink MFBG |
| |
|
The INTERCEPT Blood System for Plasma: Process Validation Studies of Coagulation Factor Activity and Yield in Three European Blood Centers
|
| Pinkoski L, Cazenave JP, Hervig T, Schlenke P, Corash L |
| |
|
The Interface between the EGF2 Domain and the Protease Domain of Activated Factor IX Contributes to Cofactor Binding and Substrate Recognition
|
| Fribourg C, Mertens K |
| |
|
The IVS1-401 T-Allele of the Estrogen Receptor (ER)-a is an Independent Predictor of Late Fetal Loss
|
| Zotz RB, Gerhardt A, Mikat-Drozdzynski B, Krüssel JS, Bender HG, Scharf RE |
| |
|
The Japanese Vein Study: The 2nd Survey of Deep Vein Thrombosis
|
| Yamaki T, Hirai M, Ohta T, Matsuo H, Koyano K |
| |
|
The Junctional Adhesion Molecule-C Promotes Neutrophils Transendothelial Migration in vitro and in vivo
|
| Chavakis T, Keiper T, Matz-Westphal R, Hersemeyer K, Sachs UJH, Nawroth PP, Preissner KT, Santoso S |
| |
|
The Long-term Future of Patients Had Had Henoch-Schonlein Purpura in Childhood
|
| Iatsenko EA, Plahuta TG, Soskov GI, Larina LE |
| |
|
The Lupus Ratio Test for Detection of Lupus Anticoagulants: Evaluation of Two Fully Automated aPTT-based Procedures That Use Commercially Available Reagents
|
| Kershaw G, Suresh S, Joshua D |
| |
|
The Management of Congenital FVII Deficiency
|
| Mariani G |
| |
|
The Marburg I SNP (G511E) of Factor VII Activating Protease (FSAP), Which Is Linked to Atherothrombosis, Exhibits Diminished Proteolytic Activity
|
| Muhl L, Shibamiya A, Kemkes-Matthes B, Weimer T, Preissner KT, Kanse SM |
| |
|
The Mechanism of Alpha-1-Protease Inhibitor Inactivation During Sepsis-Induced Disseminated Intravascular Coagulation
|
| Samis JA, Stewart KA, Toh CH, Downey C, Wong D, Nesheim ME |
| |
|
The Molecular Characterization of Apo E and Its Association with Serum and Platelet Membrane Lipids in Familial Hypercholesterolaemia (FH)
|
| Chetty N, Naran NH, Raal FJ |
| |
|
The Molecular Structure of the Antigen in Heparin-induced Thrombocytopenia
|
| Greinacher A, Gopinadhan M, Günther JU, Omer-Adam MA, Stobel U, Warkentin TE, Papastavrou G, Weitschies W, Helm CA |
| |
|
The Monitoring FEIBA Therapeutic Effect in a Haemophiliac with an Inhibitor by the Method of Thrombelastography
|
| Haj[scaron]manová Z, [Scaron]lechtová MUDr.J, Mokrej[scaron] MUDr. J |
| |
|
The Mutational Spectrum of Type 1 Von Willebrand Disease (VWD): Results from the Canadian Type 1 VWD Study
|
| James PD, Notley CRP, Hegadorn C, Brown C, Tinlin S, Andrews C, Labelle A, Leggo J, Tuttle A, O'Brien L, Hough C, Rivard GAHCDC, Lillicrap D |
| |
|
The National Register of Patients with Inherited Coagulopathies in Russia
|
| Plyushch OP, Zozulya NI |
| |
|
The New Anticoagulant Octaparin Displays High Antithrombotic Action in Venous Thrombosis in Rabbits and Rats without Impairment of Hemostasis
|
| Laux V, Just M, Rosenburg R, Lorenz M, Viskov C |
| |
|
The New Single Nucleotide Polymorphisms of Adp Receptor P2y12 Gene Affected Platelet Aggregation and Myocardial Infarction Development Were Found in Russia
|
| Sirotkina O, Novikova A, Vavilova T |
| |
|
The Nijmegen Haemostasis Assay to Study the Interplay between Coagulation and Fibrinolysis
|
| van Heerde WL, Lap P, Loof A, Novakova I, van Kraaij M, Verbruggen H, Boezeman J |
| |
|
The Nijmegen Hemostasis Assay Is a Useful Tool to Screen Thrombophilia
|
| van Heerde WL, Lap P, Willemsen M, Roumen E, van Kraaij mgJ, Verbruggen H |
| |
|
The Occasions of Factor XII Deficiency in Children
|
| Vdovin V, Svirin P, Shiller E, Lavrentyeva I, Luchinkina E |
| |
|
The Older Hemophilia Patient with Inhibitors: Issues and Challenges
|
| Kulkarni R, Penner JA, Bosma K, Gera R, Scott-Emuakpor A |
| |
|
The Opposing Roles of Monocytes in Atherosclerosis
|
| Medbury H, Guiffre A, Vicaretti M, Fletcher J |
| |
|
The Oral, Direct Factor Xa Inhibitor – BAY 59-7939 – Inhibits Thrombin Generation in vitro after Tissue Factor Pathway Activation
|
| Gerotziafas GT, Elalamy I, Chakroun T, Perzborn E, Depasse F, Samama M-M |
| |
|
The Palmitolyated Cysteine 595 Residue of PECAM-1 Is Required for Constitutive Association of PECAM-1 into Membrane Microdomains
|
| Coyne S, Harbour SN, Sardjono CT, Parton RG, Jackson DE |
| |
|
The PAR-1 IVSn-14 A/T Polymorphism Influences TRAP-Induced Platelet Calcium Mobilisation and Platelet Procoagulant Responses
|
| Smith SMG, Judge HM, Peters G, Gaussem P, Daly ME, Storey RF |
| |
|
The Perioperative and Periprocedural Management of Warfarin: The PPMW Study
|
| Jaffer AK, Brotman DJ, White RH |
| |
|
The PFA – 100: Platelet Function Screening–The Queensland Health Pathology Service (Q.H.P.S.) Experience
|
| Just S, Kennedy G, Rowell J, Williams B |
| |
|
The Pharmacogenetics and Inhibitor Risk (PIR) Study: Do the Multiple Forms of Wildtype Factor (F)VIII Contribute to the Development of Anti-FVIII Antibodies in Hemophilia a Patients during Coagulation Factor Replacement Therapy?
|
| Machiah DK, Tran TT, Viel KR, Shen M, Howard TE |
| |
|
The Phospholipid Composition of Cell-derived Microparticles Changes in the Postprandial State
|
| Tushuizen ME, Peypers EG, Snoeck DP, Hoek FJ, Sturk A, Heine RJ, Nieuwland R, Diamant M |
| |
|
The Platelet Actin Cytoskeleton Dynamically Reorganizes into Podosomes Upon Cell Adhesion. Identification of a Novel Actin-rich Adhesive Structure in Human Platelets
|
| Dyson JM, Ooms LM, Brown S, Becanovic J, Falet H, Hartwig JH, Berndt MC, Mitchell CA |
| |
|
The Platelet Contribution to Elastic Properties of Blood and Plasma Clots – Differences in Measuring Range between FOR and ROTEM
|
| Ramström S, Lindahl TL |
| |
|
The Platelet/Endothelial Cell Adhesion Protein F11R (a.k.a. JAM-1) Is Present in Cerebral Blood Vessels, Meninges, the Choroid Plexus and on Neuronal Cells
|
| El-Idrissi A, Levinskaya N, Kornecki E, Babinska A, Ehrlich YH |
| |
|
The Possible Protective Role of FXIII Leu34 Allele in Thromboembolic Episodes. Its Coexistence with FVL and PAI-1 (4G/5G) Mutations in Thrombophiliacs
|
| Tsaousidou M, Girtovitis F, Ioannidis G, Makris PE |
| |
|
The Predictive Value of D-Dimers on the Occurrence of Thromboembolic Events and Death: A Prospective Multicentric Study
|
| Mahé I, Drouet L, Chassany O, Bal dit Sollier C, Mazoyer E, Minh-Muzeaux1 S, Caulin C, Bergmann JF, for the COAGFA Group |
| |
|
The Prevalence of Low von Willebrand Factor Activity and von Willebrand Disease Among Young Women with Bleeding Symptoms
|
| Friberg B, Hillarp A, Ekholm C, Mattson E, Lethagen S |
| |
|
The Prevalence of the Human Glycoprotein PC-1 Gene Polymorphism (K121Q) and Its Association with Type II Diabetes and Insulin Resistance in the South African Inter Ethnic Population
|
| Naran NH, Chetty N |
| |
|
The Prevalence of Von Willebrand's Disease in Trakya Region of Turkey
|
| Kundak T, Demir M, Eskiocak M, Beyzadeoglu H, Vural O, Biner B, Ugurlu T |
| |
|
The Prognostic Value of the D-Dimer Test in Cancer Patients Treated with and without Low-Molecular-Weight Heparin
|
| Di Nisio M, Klerk CPW, Meijers JCM, Büller HR |
| |
|
The Promise and Challenges of Bioengineered Recombinant Clotting Factors
|
| Pipe SW |
| |
|
The Prothrombin G19911A Is a Functional Non-coding Polymorphism
|
| van der Putten HHAGM, Spaargaren-van Riel CC, Bertina RM, Vos HL |
| |
|
The PROVE Registry: A Prospective Registry on Venous Thromboembolic Events
|
| Turpie AGG |
| |
|
The Proximal C-terminal Domains of ADAMTS13 Determine the Recognition and Cleavage of Peptidyl Substrate VWF73 and Macromolecular Substrate von Willebrand Factor
|
| Ai J, Smith P, Wang S, Zheng X |
| |
|
The P-selectin, Tissue Factor, Coagulation Triad
|
| Wagner DD |
| |
|
The Rap1 Activation Mechanism in Platelets: It is Related to the Release Reaction Mediated Through the Collagen Receptor Glycoprotein (GP) VI
|
| Moroi M, Ohnuma M, Watanabe N, Sonoda M, Handa M, Jung SM |
| |
|
The Relation Between in vitro Thrombin Generation and Signs of in vivo Thrombin Generation; Influence of Pro- and Anti-coagulant Plasma Factors
|
| Al Dieri R, Béguin S, Scarabin PY, Alhenc Gelas M, Hemker HC |
| |
|
The Relation of Dosing to Clopidogrel Responsiveness and the Incidence of High Post-Treatment Platelet Aggregation in Patients Undergoing Coronary Stenting
|
| Gurbel PA, Bliden KP, Hayes KK, Yoho J, Kreutz Y, Tantry U |
| |
|
The Relation of Laboratory and Clinical Features to the Response to Plasma Exchange Therapy in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (TTP)
|
| Böhm M, Betz C, Krause M, Von Auer C, Miesbach W, Scharrer I |
| |
|
The Relationship Between Genetic Variants in the Endothelial Protein C Receptor and Venous Thromboembolism
|
| Hooper WC, Lally C, Benson J, Dowling N, Austin H |
| |
|
The Relationship Between Hypercoagulable State and Sudden Sensory Neural Deafness
|
| Sulistya AB, Hadjar E, Bashiruddin J, Tambunan KL, Setiabudy R |
| |
|
The Relationship Between INR Time-In-Range and Risk of Stroke and Major Bleeds in Chronic Non-Valvular Atrial Fibrillation Warfarin Utilizers
|
| Stephenson JJ, Fernandes JO, Beaulieu JF, del Aguila MA, Hauch O, Kim J, Boccuzzi SJ |
| |
|
The Relationship between Pro-Inflammatory Cytokine Levels and Fibrinolytic System in Simple Obese Patients
|
| Gerenli M, Tugrul A, Demir M, Arikan E, Guldiken S, Azcan S |
| |
|
The Relationship between Venous Thrombosis and Inflammation: A Systematic Review of Clinical Studies
|
| Kahn SR, Fox E |
| |
|
The Relationship of the GAS6 Gene to Myocardial Infarction in African-Americans and Caucasians
|
| Hooper WC, Lally C, League S, Austin H |
| |
|
The Release of Tissue Factor Bearing Microparticles from a Human Urinary Bladder Tumor Cell Line Following Chemotherapy
|
| Weber H, Kollars M, Eichinger S, Kyrle PA, Weltermann A |
| |
|
The Rise of Plasminogen Activator Inhibitor-1 Activity in Coronary Artery Bypass Grafting of Type 2 Diabetes Patients
|
| Sembiring RJ, Supari F, Sutomo K, Tambunan KL |
| |
|
The Risk of Proximal DVT and Pulmonary Embolism (PE) in Patients with Objectively Verified Arterial Thrombosis. A Population-Based Autopsy Study
|
| Eliasson Å, Bergqvist D, Björck M, Acosta S, Sternby NH, Ögren M |
| |
|
The Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Patients with Acute Deep Vein Thrombosis or Pulmonary Embolism. A Multicentre Prospective Cohort Study in 1626 Patients
|
| Prandoni P, Ghirarduzzi A, Pengo V, Noventa F, Bernardi E |
| |
|
The Risk of Venous and Arterial Thrombosis in Patients with HIV Infection
|
| Micieli E, Ageno W, Grossi P, Venco A |
| |
|
The Risk of Venous Thrombosis Increases with Co-existence of Multiple Genetic Abnormalities: A Comprehensive Study in Kuwait
|
| Jadaon MM, Dashti AA |
| |
|
The Role of Annexin A5 and Anti-Annexin A5 Antibodies in the Antiphospholipid Syndrome
|
| van Heerde WL, de Laat HB, Schoormans S, Adam M, Woodhams B, Derksen RHWM, de Groot PG |
| |
|
The Role of Dalteparin for Perioperative Prophylaxis of Thromboembolism in Breast Cancer Patients
|
| Sturm D |
| |
|
The Role of Endothelial Cell Apoptosis in Inflammatory and Immune Disease
|
| Winn R, Harlan J |
| |
|
The Role of Gamma-Glutamyltransferase Activity on Early Platelet Apoptotic Process
|
| Sener A, Ozsavci D, Demirel GY, Aksoy H, Oba R, Uras F, Yardimci KT |
| |
|
The Role of Low Doses Anti-TNF In Improvement of Immune Function in PAD Patients after Late Thrombosis
|
| Svetlikov A, Barsukov A, Gamzatov T, Gaikovaya L |
| |
|
The Role of Mild Forms of Coagulopathias and Pathology of Platelets in the Development of Menorrhagia and Metrorrhagia
|
| Tomilin V, Voznyuk V, Vasilchuk G |
| |
|
The Role of Mild Forms of Coagulopathias and Pathology of Platelets in the Development of Menorrhagia and Metrorrhagia
|
| Tomilin V, Voznyuk V, Vasilchuk G |
| |
|
The Role of PAI-1 Deficiency and a Reduced Capacity to Generate Activated Protein C on Coagulation Activation and Fibrin Formation during Murine Influenza Pneumonia
|
| Keller TT, van der Sluijs KF, Mairuhu ATA, Gerdes VEA, van Gorp ECM, Meijers JCM, van der Poll T, Büller HR, Brandjes DPM, Levi MM |
| |
|
The Role of Platelet Factor 4 and the Use of Dextran Sulfate in Anti Factor Xa Assays: Overestimation of Anticoagulant Activity in LMWH Therapy?
|
| Wilmer M, Rudin K, Bühler B, Calatzis A, Peetz D |
| |
|
The Role of Serotonin and Melatonin on Hematopoiesis and Platelet Production
|
| Yang M, Li K, Huang WZ, Liu AG, Pong NH, Chuen CKY, Fok TF |
| |
|
The Sensitive Detection of Antibodies to von Willebrand Factor Cleaving Protease (ADAMTS-13)
|
| Starke R, Mackie I, Purdy G, Scully M, Machin S |
| |
|
The Spectrum of Mutations and Molecular Pathogenesis of Haemophilia A in 163 Portuguese Patients
|
| David D, Ventura C, Kemball-Cook G, Diniz MJ, Antunes M, Tavares A, Araújo F, Morais S, Campos M, Moreira I, Lavinha J |
| |
|
The SSC/ISTH Secondary Coagulation Standard in UK NEQAS for Blood Coagulation Proficiency Testing Exercises: Assigned Values for FV:C and FXI:C Should Assist in the Standardisation of These Assays
|
| Woods TAL, Jennings I, Kitchen S, Kitchen DP, Preston FE, Walker ID |
| |
|
The Stable Prostacyclin Analog Iloprost Induces The Production of the Angiogenic Factor Oncostatin M by Monocytes in a p38K-dependent Pathway
|
| Vasse M, Eugène S, Legrand E, Campart D, Vannier JP |
| |
|
The State of Fibrinolytic and Coagulation Systems in Hemophiliacs
|
| Grigorjeva M, Golubeva M, Jakunina L, Vdovin V |
| |
|
The Study of Genetics Risk Factors Predisposing to Myocardial Infarction in Young Men
|
| Sheydina A, Pchelina S, Rodigina T, Demina E, Schwarzman A |
| |
|
The Substrate-Membrane Interaction Constrains Bond Presentation and Cleavage in the Action of Human Prothrombinase on Prothrombin
|
| Orcutt S, Krishnaswamy S |
| |
|
The Tetraspanin CD63 and Phosphatidylinositol 4-Kinase Type II Co-Localize in Resting Platelets and Are Associated with Lipid Rafts Following Platelet Activation
|
| Israels SJ, McMillan-Ward EM |
| |
|
The TF 5466 a/G SNP is a Novel Regulator of Tissue Factor Expression
|
| Siegbahn A, Mälarstig A |
| |
|
The Thrombin-Thrombomodulin Complex Activates Nitric Oxide Synthase 3 through Calmodulin Kinase II and Phosphoinositide 3-kinase Signalling
|
| David-Dufilho M, Millanvoye-Van Brussel E, Topal G, Brunet A, Rendu F |
| |
|
The Thrombogram in Twins, Influence of Oral Contraceptive and Intercurrent Infection
|
| Al Dieri R, Joosen AMCP, Carlo A, Béguin S, Hemker HC |
| |
|
The Time Courses of Fibrin Formation, Prothrombin Activation and TAFI Activation in Normal and Factor VIII-Deficient Plasma
|
| Foley JH, Kim PY, Yu AYH, Ward VA, Nesheim ME |
| |
|
The TM -1208/-1209delTT Gene Promoter Polymorphism and Circulating Monocyte Thrombomodulin (TM) Gene Expression in 100 Healthy Volunteers
|
| Fontana P, Reny JL, Remones V, Bieche I, Desvard F, Alhenc-Gelas M, Gaussem P, Aiach M |
| |
|
The TNF Alpha Converting Enzyme (TACE/ADAM17) Is Expressed in the Atherosclerotic Lesion of ApoE-deficient Mice
|
| Canault M, Peiretti F, Kopp F, Bonardo B, Juhan-Vague I, Nalbone G |
| |
|
The Use of Calibrated Automated Thrombin Generation to Detect Alterations of the Clotting System Brought About by Hormone Administration in Pre- and Postmenopausal Women
|
| Al Dieri R, Hemker HC, Béguin S, Guillonneau S, Scarabin PY, Alhenc Gelas M |
| |
|
The Use of Cow-Brain Tissue as an Alternative Source of Tissue Thromboplastin for Prothrombin Time Tests
|
| Lugos MD, Ali S, Erahbor T |
| |
|
The Use of DD2-DD6 Anti-D-Dimer MAb Pair For the Determination of Cross-linked Fibrin Degradation Products is a Possible Solution of D-Dimer Standard Problem
|
| Kogan A, Filatov V, Kara A |
| |
|
The Use of Factor VII(rFVIIa) in Surgical Correction of Hypospadiasis in a Child with Haemophilia A Complicated by Presence of Factor VIII Inhibitor
|
| Laguna P, Klukowska A, Matysiak M |
| |
|
The Use of Laserotherapy in Elderly Patients with Unstable Angina
|
| Alizade I, Aliyeva-Karayeva N |
| |
|
The Use of Recombinant Activated Factor VII to Control Postoperative Bleeding in Patients Undergoing Abdominal Aortic Aneurysm Reconstruction
|
| Terlecki P, Przywara S, ZubilewiczH[lstrok]awacz-Paszczyk TB, PrzesmyckiK[ecedil]sik KJ, Paluszkiewicz A, Ilzecki M, Wro[nacute]ski J |
| |
|
The Use of Recombinant Factor VIIa (rFVIIa) for the Treatment and Prevention of Excessive Bleeding in Non-Hemophiliac Children
|
| Young G, Wicklund BM, Johnson C, Neff P, Nugent DJ |
| |
|
The Use Of ROTEM for the Evaluation of Effectiveness of Recombinant FVIIa Administration in Patients with Uncontrollable Bleeding
|
| Kotsi P, Anastasopoulou I, Katsarou O, Tsoukala C, Markakis K, Karafoulidou A |
| |
|
The Use of Temporary IVC Filters for the Prevention of Pulmonary Embolism in High Risk Patients
|
| Gibbs H, Harper J, Leggett D, Wong L, Neals M |
| |
|
The Use of the Thromboelastograph and Rotem in Monitoring Recombinant Factor VIIa
|
| Parmar K, Hunt BJ |
| |
|
The Utility of TGN 255 in a Model of Coronary Pulmonary Bypass and Simulated Mitral Valve Repair in the Dog
|
| Kennedy A, Dupe R, Nelson D, Chahwala S, Chander C, Fossum T |
| |
|
The Variability of Platelet Function Testing
|
| Hevelow ME, McKenzie SE, Siegel JE |
| |
|
The VASP Index: A New Reliable Method to Detect Response Variability after Clopidogrel
|
| Udaya T, Kevin B, Jason Y, Kevin H, Rolf K, Kazi Z, Paul AG |
| |
|
The VEINES-QOL/Sym Questionnaire Is a Valid and Reliable Measure of Quality of Life in Patients with Deep Venous Thrombosis
|
| Kahn SR, Lamping DL, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L |
| |
|
The Vitamin K Cycle
|
| Stafford DW |
| |
|
The Whole Blood Coagulation Profile in Hyperhomocysteinemic Patients with Prior Thrombosis is Changed by Folic Acid Treatment as Evaluated by roTEG Thrombelastography
|
| Ebbesen LS, Christiansen K, Ingerslev J |
| |
|
The Whole Blood Platelets Aggregation Test for HIT Diagnosis
|
| Lépine-Martin M, Fontaine A, Alcindor T, Beauregard P, Delisle L, Dufresne J, Rochon M, St-Onge C |
| |
|
The WIP-WASp Complex Modulates Platelet Signaling and Function
|
| Falet H, Geha RS, Hartwig JH |
| |
|
Therapeutic Endogenous Ligand/Receptor Induction of the VEGF-Angiopoietin System after Intramyocardial Gene Transfer during Myocardial Ischemia
|
| Siddiqui AJ, GustafssonMånsson-Broberg TA, Grinnemo KH, Dellgren G, Hao X, Fischer H, Sylvén C |
| |
|
Therapeutic Inhibition of Endothelial Tissue Factor Expression by Nitric Oxide and Other Agents in Sickle Transgenic Mice
|
| Kollander R, Solovey A, Choong S, Elford H, Geng J, Kelm R, Hebbel RP |
| |
|
Therapeutic Monitoring Using Rotation Thromboelastometry in Patients with Coagulation Factor VIII Inhibitors
|
| Dehmel H, Eisert RM, Ganser A, Tiede A |
| |
|
Therapeutic Plasma Exchange (TPE) for Thrombotic Thrombocytopenic Purpura (TTP) Using Plasma Prepared With Photochemical Treatment: Clinical Responses, vWF CP Levels and vWF-CP Inhibitor Levels
|
| Mintz PD, Neff A, MacKenzie M, Hillyer C, Goodnough LT, Kessler C, McCrae K, JMenitove J, Damon L, I Lopez I, Roualt C, Crookston K, Benjamin RJ, George J, Van Doren S, Lin JS, Conlan MG, Corash L |
| |
|
Therapy of Isolated Calf Muscle Vein Thrombosis with Low-Molecular-Weight Heparin: Prospective Randomized Study
|
| Schwarz T, Thomas Z, Schellong S |
| |
|
There Is No Correlation between HPA-1a Antibody Concentration and Clinical Severity of Neonatal Thrombocytopenia in 200 Pregnancies with HPA Alloimmunisation
|
| Ranasinghe E, Ghevaert C, Campbell K, Stafford P, Allen DL, Metcalfe P, Walton J, Smith G, Williamson L, Ouwehand WH |
| |
|
Thienopyridines Pretreatment Decreases Long-Term Total Mortality in Unselected Acute Coronary Syndromes Patients Treated according to Contemporary Guidelines
|
| Flipiak KJ, Grabowski M, Glowczynska R, Karpinski G, Rdzanek A, Szpotanska M, Pierscinska-Jedra M, Cieslikiewicz D, Kochman J, Opolski G |
| |
|
Thirty Novel Mutations in the Factor VIII Gene of Indian Patients with Haemophilia A
|
| G Jayandharan, RV Shaji, SC Nair, A Viswabandya, V Mathews, B George, M Chandy, A Srivastava |
| |
|
Thomboembolic Complications and Pathogenetic Role of Nitric Oxide in Patients with Chronic Heart Failure
|
| Guzal M |
| |
|
Three Novel Heterozygous Mutations in a Patient with Type II Glanzmann Thrombasthenia
|
| Losonczy G, Boda Z, Rosenberg N, Vereb G, Kappelmayer J, Bereczky Z, Muszbek L |
| |
|
Three Novel Missense Mutations and Their Functional Consequences in Two Severe Inherited Factor X Deficiencies
|
| Bereczky Z, Kiss C, Szabó T, Bárdos H, Ajzner É, Balogh I, Komáromi I, Ádány R, Muszbek L |
| |
|
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) has Different Effects on Fibrinolysis Induced by Tissue-Type Plasminogen Activator (t-PA) and Urokinase-Type Plasminogen Activator (u-PA) in a Whole Blood Thromboelastography Model
|
| Harris SL, Gallimore MJ, Jones DW, Tappenden K, Winter M |
| |
|
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Acute Myeloid Leukaemia (AML)
|
| Sokolowski J, Kloczko J, Galar M |
| |
|
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Obliterative Atherosclerosis
|
| Galar M, Kloczko J, Sokolowski J, Pszczolka M |
| |
|
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Stable Angina Pectoris Patients Undergoing Coronary Artery Bypass Grafting (CABG)
|
| Malyszko J, Lisowski P, Hirnle T, Lisowska A, Jackowski R, Malyszko JS, Mysliwiec M |
| |
|
Thrombin Generation after Therapy with Lipid-Lowering Drugs in High Cardiovascular Risk Subjects Supplemented with Folic Acid
|
| Domagala TB, Undas A, Celinska-Löwenhoff M, Dropi[nacute]ski J, Iwaniec T, Szczeklik A |
| |
|
Thrombin Generation and Activated Protein C Resistance in Factor V Leiden Pseudo-homozygous Patients
|
| Castoldi E, Brugge JM, Simioni P, Bernardi F, Tormene D, Lunghi B, Tans G, Pagnan A, Rosing J |
| |
|
Thrombin Generation and Protein C Activity in Patients with Acute Myocardial Infarction Treated with Bivalirudin and Heparin
|
| Mycka R, Wysokinski WE |
| |
|
Thrombin Generation and Protein C Activity in Patients with Acute Myocardial Infarction Treated with Bivalirudin and Heparin
|
| Mycka R, Wysokinski WE |
| |
|
Thrombin Generation as Parameter to Monitor Patients with Thrombophilia and Pregnancy
|
| Siegemund T, Siegemund A, Scholz U, Wittig I, Henckel T, Petros S |
| |
|
Thrombin Generation Assay – A Sensitive Tool to Follow the Pharmacokinetics of Factor VIII Replacement Therapy in Haemophilia Patients
|
| McCormick AN, Váradi K, Savidge G, Turecek PL |
| |
|
Thrombin Generation in Haemophilia A Patients Does Not Necessarily Correlate with Levels of Factor VIII Detected Using Standard Factor VIII Potency Assays: A Comparative Analysis of Pre- and Post-Infusion Patients Plasmas Using Fluorogenic and Clotting Thrombin Generation Tests
|
| Raut S, Faulkner LJ, Nair S, Srivastava A |
| |
|
Thrombin Generation under Flow Conditions in the Presence of Direct and Indirect Inhibitors of Factor Xa
|
| Thomas S, Gray E |
| |
|
Thrombin Induced Upregulation of Plasminogen Activator Inhibitor 1 (PAI-1) is Mediated by a Pathway Including S100 A9 Ca++ Binding Protein
|
| Berrou J, Pluyshch T, Rerolle J-P, Vigneau C, Rondeau E, Binder BR |
| |
|
Thrombin Inhibition with Melagatran Prevents Plaque Rupture in Apolipoprotein E Knockout Mice
|
| Karanam S, Fritsche-Danielson R, Jackson C |
| |
|
Thrombin Is Required for Inflammatory Cell Recruitment and Graft Infiltration During Acute Humoral Xenograft Rejection
|
| Chen D, Weber M, McVey JH, Kemball-Cook G, Tuddenham EGD, Lechler RI, Dorling A |
| |
|
Thrombin Modulates Proangiogenic Cytokine Secretion and Cell Adhesion of Human Prostate Cancer Cells Via PAR-1
|
| Liu J, Schuff-Werner P, Steiner M |
| |
|
Thrombin Potential in Severe Haemophilia A and B Patients
|
| Davidson SJ, Burman JF, Sukhu K, Keeling DM |
| |
|
Thrombin Regulates cAMP Level in Human Platelets through Phosphorylation/Activation of Akt
|
| Zhang W, Colman RW |
| |
|
Thrombin-Activatable Factor X Re-establishes an Intrinsic Amplification in Tenase-deficient Plasmas
|
| Louvain-Quintard VB, Bianchini EP, Calmel-Tareau C, Tagzirt M, Amelot A, Le Bonniec BF |
| |
|
Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Regulates Activated Complement C5a in vivo
|
| Nishimura T, Myles T, Nagashima M, Morser J, Pearl RG, Leung LLK |
| |
|
Thrombin-Activatable Fibrinolysis Inhibitor Deficiency Influences the Inflammatory But Not the Procoagulant/Fibrinolytic Response to Escherichia coli-Induced Abdominal Sepsis in Mice
|
| Renckens R, Roelofs JJTH, ter Horst SA, van t Veer C, Havik S, Florquin S, Wagenaar GT, Meijers JCM, van der Poll T |
| |
|
Thromboelastogram Assays To Detect Hemostatic Abnormalities In Factor XIIIA Deficient Transgenic Mice: Substitution With Human Plasma Factor XIII
|
| Dickneite G, Lauer P |
| |
|
Thromboelastography Is a Useful Predictor of Stent Thrombosis
|
| Bliden K, Tantry U, Guyer K, Bassi A, Zaman K, Kreutz Y, Gurbel PA |
| |
|
Thromboembolic and Bleeding Complications during Non-cardiac Surgery in Patients with Mechanical Heart Valves
|
| Vink R, Van Dongen CJ, Jacobs R, Van den Brink R, De Mol B, Büller HR, Levi M |
| |
|
Thromboembolic Complications in 16 Patients Undergoing Free Flap Surgery
|
| Olsson E, Höijer P |
| |
|
Thromboembolic Complications of Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: Effects of the Disease and the Therapy on the Hemostatic System
|
| Carneiro JDA, D'Amico EA, Chamone DAF, Vaz FAC, Odone-Filho V |
| |
|
Thromboembolic Disease and Its Relationship with ABO-Rh Blood-Groups and Other Variables in Patients at Warfarin Clinics in Iran
|
| Mehran K, Abdolreza A, Parvin A, Bahram Z, Mohammad Ali G |
| |
|
Thromboembolic Episodes in Children: 15 years Experience from One Centre
|
| Pergantou H, Platokouki H, Kapsimali Z, Adamtziki E, Komitopoulou A, Aronis S |
| |
|
Thromboembolic Risk Adapted Dosage of Low Molecular Weight Heparin in Chronically Anticoagulated Patients with Atrial Fibrillation Prior to Interventions with High Risk of Bleeding: Experience in 400 Patients
|
| Hammerstingl C, Schmitz A, Schlang G, Schmidt H, Omran H |
| |
|
Thrombomodulin Binds Lethal Cytokine HMGB1 and Neutralizes Its Pro-inflammatory Activity: Novel Cytoprotective Action of Thrombomodulin
|
| Maruyama I, Abeyama K, Ito T, Biswas KK, Yamada S, Hashiguchi T |
| |
|
Thrombomodulin Domain as an Angiogenic Factor
|
| Wu HL, Shi CS, Kuo CH, Shi GY |
| |
|
Thrombomodulin Inhibits Tumor Cell Invasion Through Three Different Domains of the Molecule
|
| Satoh Y, Horie S, Sekizuka T, Matsuda J, Ishii H |
| |
|
Thrombomodulin Regulates Cell to Cell Junction Formation
|
| Chen PS, Huang HC, Huang CW, Shi GY, Wu HL |
| |
|
Thrombophilia and Pregnancy Outcomes
|
| Pabinger I, Vormittag R |
| |
|
Thrombophilia in a Healthy Population from Northwest Colombia
|
| Castaneda SA, Cardona H, Alvarez L, Cardona-Maya WD, Torres JD, Tobon LI, Quintero-Rivera F, Bedoya G, Gomez JG, Gomez JM, Cadavid AP |
| |
|
Thrombophilia in Inherited Antithrombin Deficiency
|
| Luxembourg B, Pavlova A, Dressler M, Mani H, Kläffling C, Oldenburg J, Lindhoff-Last E |
| |
|
Thrombophilia in Patients with Spinal Cord Injury
|
| Marcucci R, Ricci L, Fedi S, Alessandrello Liotta A, Rogolino A, Falciani M, Innocenti D, Filoni C, Aito S, Abbate R |
| |
|
Thrombophilia in Women with Unexplained Fetal Loss
|
| Bonifacio G, Grimaudo S, Lo Coco L, Malato A, Anastasio R, Siragusa S |
| |
|
Thrombophilia in Young Adults with Ischemic Stroke Not Related to Cardiovascular Risk Factors
|
| Anastasio R, Lupo E, Grimaudo S, Bonifacio G, Malato A, Lo Coco L, Siragusa S |
| |
|
Thrombophilia Is Frequent in Superficial Vein Thrombosis and Is Associated with Recurrence: A Retrospective Study
|
| Marcucci R, Ciuti G, Balgojevich E, Lenti M, Lucarini L, Rossi L, Evangelisti L, Gensini GF, Abbate R, Prisco D |
| |
|
Thrombophilia Is Not a Risk Factor for Peripheral Intravenous Infusion-Associated Thrombophlebitis
|
| Tagalakis V, Kahn SR, Libman M, Blostein M, Solymoss S, Miller M |
| |
|
Thrombophilia Markers in Cases of Inflammatory Bowel Disease (IBD)
|
| Mohanty D, Banait V, Shetty S, Ghosh K, Rathi P |
| |
|
Thrombophilia, Placental Pathology and Perinatal Cerebral Infarction: Any Relationship?
|
| Olomu IN, Omar SA, Hong T, Chamyan G, Kulkarni R |
| |
|
Thrombophilia: A New Potential Risk Factor for Cervix Insufficiency
|
| Ulander V-M, Wartiovaara U, Hiltunen L, Rautanen A, Kaaja R |
| |
|
Thrombophilia: Factor V Leiden in Patients with Cardiovascular Diseases in Slovak Population
|
| Silvanova E, Kanalikova K, Sefranek V |
| |
|
Thrombophilia-Associated Fetal Loss: Epistasis of Fetal and Maternal Factors
|
| Sood R, Hendrikson SB, Kalloway S, Zogg M, Guo Y, Mast A, Weiler H |
| |
|
Thrombophilic Mutations: A Comparison between the Microarray Technique and the Solid Phase Oligonucleotide Ligation Assay (SPOLA)
|
| Tsaousidou M, Girtovitis F, Ioannidis G, Pithara E, Makris PE |
| |
|
Thromboprophylaxis in Medical Patients with an Acute Medical Illness (Excluding Stroke and Myocardial Infarction): A Meta-analysis
|
| Alikhan R, Cohen A |
| |
|
Thromboprophylaxis with Fondaparinux in Acutely Ill Medical Patients Aged 75 years or More, or with Moderate Renal Impairment
|
| Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AGG, Egberts JFM, Lensing AWA, the ARTEMIS Investigators |
| |
|
Thrombosis Comlications in Children with Hemophilia after Insertion of Cental Venous Carheters
|
| Laguna P, Klukowska A |
| |
|
Thrombosis in Cancer Patients
|
| Ozkan M, Sari I, Kocyigit I, Er O, Eser B, Ozkul Y, Gokoz G, Cetin M, Altinbas M |
| |
|
Thrombosis in Paediatric Cancer Patients
|
| Chan AKC |
| |
|
Thrombospondin as a Regulator of von Willebrand Factor Multimer Size
|
| Pimanda JE, Ganderton T, Maekawa A, Yap CL, Lawler J, Kershaw G, Chesterman CN, Hogg PJ |
| |
|
Thrombospondin-1 Secures Thrombus Adherence in vivo by Protecting (Sub)Endothelial VWF from Leavage by ADAMTS13
|
| Bonnefoy A, Daenens K, De Vos R, Vermylen J, Lawler J, Hoylaerts MF |
| |
|
Thrombotic Risk in a Romanian Family with Protein S: Deficient Members
|
| Pacurar RM, Nicola ED, Cheveresan L, Gheorghiu E, Cheveresan M, Ionita H |
| |
|
Thrombotic Thrombocytopenic Purpura
|
| Lämmle B, Kremer Hovinga JA, Alberio L |
| |
|
Thromboxane A2 Null Mice Exhibit Resistance to Atherosclerosis and Neointima Formation in a Carotid Artery Ligation Model
|
| Lin S-W, Liu S-L, Yu I-S, Chen Y-H, Shi G-Y, Tseng H-Y, Lin S-R, Su K-I, Wu H-L |
| |
|
Thrombus Formation in vivo
|
|
| |
|
Thrombus Growth Is Mediated by Gp91phox
|
| Pignatelli P, Sanguigni S, Lenti L, Di Santo S, Ferro D, Finocchi A, Rossi P, Violi F |
| |
|
Thymidylate Synthase Enhancer Region (TSER) Is a Novel Genetic Determinant of Hyperhomocysteinemia in Ischemic Stroke Patients
|
| Kim NK, Kim OJ, Kim HS, Kim WC, Han JH, Oh D |
| |
|
Thymidylate Synthase: A Possible Independent Risk Factor for Silent Brain Infarction
|
| Kim NK, Kim OJ, Kim HS, Kim WC, Ahn JY, Yim DJ, Oh D, Park S |
| |
|
TIIICBP: The Platelet Receptor for Type III Collagen is Present into Platelet Membrane Lipid Microdomains (Rafts)
|
| Fauvel-Lafeve F, Waeckel L, Maurice P, Pires V, Sonnet P, Lemesle M, Arbeille B, Rochette J, Legrand C |
| |
|
Time Dependent Increase in Thrombus Size Formed under Flow Conditions upon Exposure to Collagen Correlates Inversely with Surface Expressed VWF
|
| Hársfalvi J, Vereb G, Szarvas M, Deckmyn H |
| |
|
Time In-Situ as a Risk Factor for Central Venous Catheter Associated Thrombosis (CVC-Clot) in Severe Hemophiliacs (SH)
|
| Komvilaisak P, Price V, Blanchette V, Floros G, Stain AM, Stephens D, Carcao M |
| |
|
Tissue Factor- and Collagen Triggered Thrombosis in vivo Relies on Platelet-Dependent Thrombin Generation in Both Arterioles and Venules
|
| Kuijpers MJE, Munnix ICA, Reutelingsperger CPM, oude Egbrink MGA, Heemskerk JWM |
| |
|
Tissue Factor and Factor VIIa Regulate Expression of Ets-1 in Prostate Cancer
|
| Kaushal V, Mehta P, Fink L |
| |
|
Tissue Factor Efficacy in Patients with Severe Hemophilia a Undergoing Total Knee Replacement
|
| Kirchmaier CM, Wegert W, Scholz T, Bassus S, Kurth A, Stumpf U, Scharrer I, Krause M |
| |
|
Tissue Factor Expression and Proinflammatory Cytokines in Viral Hepatitis
|
| Vitkovsky Y |
| |
|
Tissue Factor Expression in Human Neutrophils
|
| Nakamura S, Okamoto K, Abumiya T |
| |
|
Tissue Factor in Hemostasis and Thrombosis
|
| Mackman N |
| |
|
Tissue Factor Is Associated with a Negative Outcome of Clinical Islet Transplantation
|
| Johansson H, Lukinius A, Moberg L, Nilsson-Ekdahl K, Elgue G, Korsgren O, Nilsson B |
| |
|
Tissue Factor Is Expressed and Active on Cultured Human Trophoblast Cell Surface; Possible Regulation by Angiogenic Stimuli
|
| Lanir N, Snir A, Ohel G, Paz B, Brenner B |
| |
|
Tissue Factor Mediated Activation of Prothrombin Complex Concentrates and Its Inhibition by Anti-Thrombin Drugs
|
| Florian-Kujawski M, Maddineni J, Chyna B, Hoppensteadt D, Fareed J |
| |
|
Tissue Factor Pathway Inhibitor (TFPI) and Thrombin Activable Fibrinolysis Inhibitor (TAFI) in Juvenile Deep Vein Thrombosis
|
| Rogolino A, Gori AM, Alessandrello LA, Blagojevich J, Marcucci R, Attanasio M, Ferrini S, Abbate R, Gensini GF, Prisco D |
| |
|
Tissue Factor Pathway Inhibitor (TFPI) Contributes to the Early Anticoagulant Effect of Unfractionated Heparin (UFH) during Haemodialysis
|
| Ignjatovic V, Monagle P, Newall F, Furmedge J, Summerhayes R, Gan A, Jones C, Ross-Smith M, Ellis A, Chan A |
| |
|
Tissue Factor Pathway Inhibitor (TFPI) during Cardiopulmonary Bypass (CPB) in Children
|
| Ignjatovic V, Monagle P, Cochrane A, Furmedge J, Than J, Bennett M, Horton S |
| |
|
Tissue Factor Pathway Inhibitor (TFPI) during Heparin Therapy in the Paediatric Intensive Care Unit (PICU)
|
| Monagle P, Ignjatovic V, Newall F, Furmedge J, Gan A, Summerhayes R, DeRosa L, Shann F, Butt W, Chan A |
| |
|
Tissue Factor Pathway Inhibitor (TFPI) in Childhood Nephrotic Syndrome
|
| Abdel Gader A, AL-Mugeirin M, Al-Rasheed S, Al-Salloum A |
| |
|
Tissue Factor Pathway Inhibitor and the Risk of Recurrent Venous Thromboembolism (VTE)
|
| Hoke M, Kyrle PA, Weltermann A, Minar E, Bialonczyk C, Hirschl M, Eichinger S |
| |
|
Tissue Factor Pathway Inhibitor-2 Inhibits in vitro Endothelial Cell Migration and Angiogenesis
|
| Ivanciu L, Gerard RD, Lupu C, Lupu F |
| |
|
Tissue Factor Regulation, RhoA Localization, and Induction of Apoptosis in Human Cancer Cell Lines upon Simvastatin Treatment
|
| Åberg M, Tammik O, Tenno T, Wickström M, Siegbahn A |
| |
|
Tissue Factor Synthesis and Expression by Human Proximal Tubular Cells: the Source of Increased Urinary Tissue Factor Secretion in Disease?
|
| Lwaleed B, Vayro S, Greenfield R, Featherstone J, Speers A, Birch B, Cooper A |
| |
|
Tissue Factor Targeted Thrombomodulin (Ab(TF)-TM) – a Novel Tissue Factor Neutralizing Antibody Fused to Thrombomodulin (TM)
|
| McLean K, Masikat MR, Rumennik G, Zhou H, Alexander S, Cobb R, Gross C, Whitlow M, Light DR |
| |
|
Tissue Factor, Thrombomodulin and P-Selectin Levels Are Increased in End Stage Renal Disease
|
| Tobu M, Bansal V, Florian-Kujawski M, Maddineni J, Hoppensteadt D, Walenga JM, Fareed J |
| |
|
Tissue Factor: Lack of the Cytoplasmic Tail Results in Generation of Functional Microparticle-Associated Tissue Factor
|
| Zakarija A, Hobbs JE, Lieberman ED, Morrissey JH, Soff GA |
| |
|
Tissue Factor-Neutralizing Antibody Fused to Thrombomodulin (Ab(TF)-TM) Has Amplified Anticoagulant Efficacy in a Rat Model of Thromboembolism
|
| Wang Y-X, Wu C, Vincelette J, Riffel A, Martin-McNulty B, Wu Q, Larsen B, Light DR, McLean K |
| |
|
Tissue Plasminogen Activator (TPA) Therapy Resulting in Epidural Haemorrhage Following Intrathecal Therapy in a Pediatric Patient with Stage IV Burkitt's Lymphoma
|
| Komvilaisak P, Williams S, Brandao L, Weitzman S, Chait P, Grant R |
| |
|
To Mix with Pooled Normal Plasma or Not to Mix: A Comparative Study of Two Approaches to Assessing Lupus Anticoagulant Inhibitory Activity in the Dilute Russell Viper Venom Method
|
| Aboud M, Ward CM, Coyle L |
| |
|
Toll Like Receptor 4 Is Involved in Antiphospholipid-mediated Thrombosis: In vivo Studies
|
| Pierangeli S, Vega-Ostertag ME, Raschi E, Liu X, Meroni PL |
| |
|
Towards Harmonisation of D-dimer Assays
|
| Favaloro EJ, Bonar R, Low J, Aboud M, Wheeler M, Sioufi J, Lloyd J, Street A, Marsden K |
| |
|
t-PA Enhances NMDA-Induced Changes in Free Intracellular Calcium in Individual Neurons
|
| Samson A, Medcalf RL |
| |
|
Transcranial Color Doppler Sonography in the Diagnosis of Middle Cerebral Artery Spasm
|
| Mariak Z, Mariak Z, Krejza J, Kochanowicz JNM |
| |
|
Transcriptional Regulation of PLC-b2 Gene in Human Megakaryocytic Cell Line
|
| Mao G, Kunapuli S, Rao AK |
| |
|
Transcriptional Regulatory Elements in the 5'-Upstream Region of Gaq Gene in a Human Megakaryocytic Cell Line
|
| Jalagadugula G, Dhanasekharan D, Rao AK |
| |
|
Transcriptome of Vascular Endothelium in Angiogenesis: Isolation and Characterization of a Novel Endothelium-Derived Angiogenesis Inhibitor, Vasohibin
|
| Sato Y |
| |
|
Transendocardial Autologous Bone Marrow Cell Transplantation in Patients with Advanced Ischemic Heart Disease – A Multi-Center Feasibility Study
|
| Fuchs S, Kornowski R, Weisz G, Satler LF, Smits PC, Okubagzi P, Baffour R, Aggarwal A, Weissman NJ, Cerqueira M, Waksman R, Serrruys P, Battler A, Moses JW, Leon MB, Epstein SE |
| |
|
Transfusion of Blood Products in Trauma Patients with Lethal Hemorrhagic Shock
|
| Kamphuisen PW, Geeraedts LMG, Demiral HM, Schaap NP, Frölke JPM |
| |
|
Treatment and Management of Women with Bleeding Disorders and Menorrhagia (WBDM) Study: Laboratory Diagnosis
|
| Miller CH, Dowling N, Kouides PA, Philipp CS, Stein SF, Kulkarni R, Lukes A, Crudder S |
| |
|
Treatment of 51 Pregnancies with Danaparoid Because of Heparin Intolerance
|
| Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN |
| |
|
Treatment of Acute Angioedema Attack with Icatibant in a Patient with Hereditary Angioedema due to C1-Inhibitor-Deficiency
|
| Aygoren-Pursun E, Martinez Saguer I, Stoll H, Rusicke E, Klingebiel T, Kreuz W |
| |
|
Treatment of Chronic Hepatitis C Infection in Patients with Hemophilia or Von Willebrand Disease with a Combination of Pegylated Interferon and Ribavirin
|
| Lethagen S, Stigendal L, Berntorp E, Holmström M, Schulman S |
| |
|
Treatment of Congenital Coagulation Disorders in Countries with Limited Financial Resources – Bulgarian Experience
|
| Lissitchkov T, Zarkova A, Kalev I, Gaidarov B, Nedevsky J |
| |
|
Treatment of Extensive Venous Malformation-Associated Localized Intravascular Coagulation with Interferon-Alpha: Case Report
|
| Okazaki E, Bezerra-Neto JE, Linardi CCG, Bassitte RP, Villaça PR, Chamone DAF, D'Amico EA |
| |
|
Treatment of Glanzmann's Thrombasthenia (GT): A Prospective Observational Registry on the Use of Recombinant Human Activated Factor VII (rFVIIa) and Other Hemostatic Agents
|
| Poon M-C, Zotz R, di Minno G, Abrams Z, Knudsen JB, Laurian Y |
| |
|
Treatment of Hemophilia Using Long-Term Venous Access Catheters: A Prospective Multicenter Clinical Trial
|
| Harrison JA, Powell JS |
| |
|
Treatment of HIV Associated Thrombotic Thrombocytopenic Purpura-Importance of Prompt Diagnosis
|
| Scully M, Miller R, Cohen H, Roedling S, Starke R, Edwards S, Mackie I, Machin S |
| |
|
Treatment of Life Threatening Bleeding with rFVIIa in 2001–2004 in Czech Republic. Presentation of 126 Cases with the Help of ‘UniSeven’ Registry
|
| Blatny J, Cerny V, Penka M, Brabec P, Dusek L |
| |
|
Treatment Options for von Willebrand's Disease
|
| Federici AB |
| |
|
Treatment with Gelatin Absorbed Clodronate in the Management of Immune Thrombocytopenic Purpura in a Rat Model
|
| Li P, Tan ZH, Zhu Y, Ji X, Ding S, Jiang X |
| |
|
Treatment with Pasteurized C1 Inhibitor Concentrate in Abdominal Pain Attacks of Patients with Hereditary Angioedema
|
| Bork K, Meng G, Staubach P, Dewald G |
| |
|
Troponin I and In-Hospital Outcome in Patients with Non-Massive Central Pulmonary
|
| Gallotta G, Palmieri V, Piedimonte V, Rendina D, De Bonis S, Russo V, Celentano A, Postiglione A, Di Minno M |
| |
|
TRPC Associations in Human Platelets
|
| Sage SO, Brownlow SL |
| |
|
Twins Pregnancy in the Case of Essential Thombocythemia: A Case Report
|
| Lejniece S, Lejnieks A, Dunska V |
| |
|
Two Heterozygous Mutations of F8 Gene in a Female with Hemophilia A
|
| Cai XH, Wang HL, Wang XF |
| |
|
Two Isoforms of Factor X Is Produced in the Liver of Pseudonaja Textilis
|
| Reza MA, Swarup S, Kini RM |
| |
|
Two Novel Type 1 Von Willebrand Disease Causing Mutations (G160W and N166I) in the Von Willebrand Factor Propeptide, Identified in the European Study MCMDM-1VWD, Are Responsible for Multimerization And Secretion Defects
|
| Ribba AS, Stepanian A, Habart D, Hilbert L, Peake I, Goodeve A, Rodeghiero F, Castaman G, Federici A, Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F |
| |
|
Two Parallel Prothrombin Activator Systems in Eastern Brown Snakes
|
| Le TNM, Reza MA, Swarup S, Kini RM |
| |
|
Two Subpopulations of Activated Platelets Differ in Their Binding of the Components of the Intrinsic fX-Activating Complex
|
| Panteleev MA, Ananyeva NM, Ataullakhanov FI, Saenko EL |
| |
|
Two-Phase Antithrombotic Protection after Anti-GPVI Treatment in Mice
|
| Schulte V, Gachet C, Cazenave JP, Nieswandt B |
| |
|
Type 2 Diabetes: Endothelium Lesion and Fibrinolytic System Markers Assessment
|
| Soares AL, Carvalho MG, Fernandes AP, Sousa MO, Lasmar MC, Garcia ML, Novelli BA, Dusse LMS, Vieira LM, Lages GFG, Cardoso JE |
| |
|
Type II Mutation (Glu117stop) Causes Factor XI Deficiency by Inducing Allele Specific mRNA Degradation
|
| Soldà G, Asselta R, Ghiotto R, Malcovati M, Tenchini ML, Castaman G, Duga S |
| |
|
Tyr1605-Met1606 Flanking the Von Willebrand Factor Cleavage Site Are Not Required for Cleavage of VWF by ADAMTS13
|
| Schneppenheim R, Angerhaus D, 0bser T, Will K, Budde U |
| |
